Moderna has described its experimental melanoma treatment as a “landmark moment,” reporting that the vaccine could play a critical role in preventing the deadliest form of skin cancer from spreading or returning. The results stem from a Phase 3 clinical trial, which represents the final stage of testing before the data is submitted for Food and Drug Administration review.
The study involved more than 1,100 participants diagnosed with advanced-stage melanoma. medical correspondent Dr. Céline Gounder, who has personal experience with the disease, the trial represents “a big win for mRNA vaccines against cancer.” Following the announcement, Moderna’s stock price more than doubled during Wednesday morning trading.
The vaccine development process is highly personalized. After a patient’s tumor is surgically removed, it is analyzed to identify unique genetic mutations. Dr. Jon LaPook, chief medical correspondent, explained that artificial intelligence is utilized to determine which of the hundreds of identified mutations should be incorporated into the specific dose for that patient.
The treatment functions by delivering synthetic mRNA into cells, creating a “one-two punch” when combined with Merck’s cancer immunotherapy drug, Keytruda. “Cancer can put a cloak of invisibility around itself so the immune system can’t see it, and the first punch is a drug called Keytruda, which removes the cloak,” Dr. LaPook noted. Once the patient’s cells read the mRNA, they produce a protein that trains the immune system to recognize and attack the cancer.
“Think of it like giving a scent to a bloodhound. The vaccine gives the immune system the scent of melanoma so the immune system can hunt it down and kill it,” Dr. LaPook added. For patients whose cancer had reached the lymph nodes or progressed deeper into the skin, the combination of the mRNA vaccine and Keytruda provided a “statistically significant and clinically meaningful improvement” in keeping patients cancer-free for longer durations compared to standard treatment alone.
Melanoma remains a significant public health concern, ranking as the fifth most commonly diagnosed cancer in the United States. Data from the American Cancer Society indicates approximately 112,000 new cases are diagnosed annually, with projections suggesting that roughly 8,500 people in the U.S. will succumb to the disease this year. The report also notes that the groundbreaking clinical trial studied over 1,100 people whose melanoma was in advanced stages, taking a piece of a patient’s tumor and using it to build a shot, medical correspondent Dr. The report also notes that here’s what to know about the melanoma vaccine. The report also notes that how does the melanoma vaccine work. The report also notes that artificial intelligence is then used to help scientists figure out which of the hundreds of mutations should be included in the vaccine. The report also notes that surgeons had already removed their tumors, and everyone had been treated with Keytruda, the standard immunotherapy, for those participating in the trial. The report also notes that shapiro on data center order: “I don’t want developers running roughshod. The report also notes that michael Cohen, Trump’s fixer-turned-nemesis, says he’ll interview former boss. The report also notes that publix frozen blueberry recall upgraded to highest health risk level.
Source: CBS News
